Missouri Testosterone Therapy Lawyers, Peterson & Associates, P.C., Review FDA Panel Recommendations in Light of Testosterone Therapy Lawsuits - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
September 30, 2014 Newswires
Share
Share
Post
Email

Missouri Testosterone Therapy Lawyers, Peterson & Associates, P.C., Review FDA Panel Recommendations in Light of Testosterone Therapy Lawsuits

PR Web

Kansas City, MO (PRWEB) September 30, 2014

The testosterone lawsuit attorneys at Peterson & Associates, P.C. urge patients and doctors to review and follow the recommendations released by the U.S. Food & Drug Administration's (FDA) testosterone advisory panel on the heart attack and stroke risks posed by testosterone therapy.

According to a Sept. 17, 2014 report from the New York Times, the medical experts on the FDA advisory research panel voted almost unanimously in a 20-1 decision to recommend that testosterone therapy drugs be relabeled. The panel suggested that the new labels clearly indicate that the drugs should not be prescribed to men who are experiencing decreased libidos, exhaustion, or other non-testosterone related complications.

Testosterone therapy is supposed to be used to replace low levels of testosterone in men in order to improve the health effects associated with low levels of testosterone. But the New York Times article noted that millions of prescriptions are written without ever assessing the initial testosterone levels of patients.

The article noted that when testosterone drugs first emerged on the market they were prescribed only to men with serious testosterone deficiencies. A January 2014 safety announcement from the FDA stated "[t]estosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition."

However, the number of American men who take testosterone therapy drugs numbers over 5 million. For the majority of the individuals who are prescribed these drugs, the underlying issues are a function of aging rather than low levels of testerstone. The panel urged the FDA to limit marketing and insurance coverage of testosterone therapy drugs for off-label use.
According to court documents, over 200 federal lawsuits have been filed against the makers of popular testosterone drugs such as AndroGel, Axiron and Testim. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545).

The lawsuits have been consolidated into a multidistrict litigation proceeding underway in the U.S. District Court, for the Northern District of Illinois (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545).

Peterson & Associates, P.C. attorneys are offering free case evaluations to men who have experienced episodes of cardiac arrest or a stroke incident after being prescribed testosterone supplements. Families who have lost a loved one due to heart attack or stroke after testerone therapy can also request a free legal consultation.

About Peterson & Associates, P.C.
Peterson & Associates, P.C. is an elite personal injury law firm that represents the interests of clients who are injured. The firm's skilled litigators hold negligent parties responsible when they cause serious accidents and severe injuries.

For decades, the attorneys at Peterson & Associates, P.C., have served clients in and around Kansas City, Missouri resolve all of their personal injury matters. To learn more about the firm's services visit http://www.petersonlawfirm.com. Individuals interested in contacting the firm to discuss legal issues, may call 1-800-305-7552 or 816-888-8888.

Read the full story at http://www.prweb.com/releases/peterson-and-associates/testosterone-lawsuits/prweb12209769.htm

Copyright:  (c) 2014 PRWEB.COM Newswire
Wordcount:  493

Newer

Members lament Elm City Market demise

Advisor News

  • Flourish brings private-bank-like cash solution to MassMutual’s network
  • Majority of Americans concerned recent market highs are unsustainable
  • GLP-1 users choose between medication and retirement saving
  • Gen X and millennials seek new retirement model
  • Are families ready for the costs of aging at home?
More Advisor News

Annuity News

  • New class-action lawsuit targets Delaware Life over annuity disclosures
  • A client remarried: Does their annuity still fit?
  • Gen X and millennials seek new retirement model
  • Global Atlantic names Dan Farrelly head of IMO and IBD channels
  • A rising retirement challenge: The license to spend
More Annuity News

Health/Employee Benefits News

  • NABIP urges Congress to address underlying healthcare costs
  • Understanding health insurance: What fraud, waste, and abuse mean for your healthcare
  • Fairview sues UnitedHealthcare over 2027 Medicare plan info
  • Women can face challenges in obtaining LTCi
  • Health affordability task force considers utility model
Sponsor
More Health/Employee Benefits News

Life Insurance News

  • Life insurance applications rise 15.2% in September, MIB reports
  • Flourish brings private-bank-like cash solution to MassMutual’s network
  • What ‘above and beyond’ means for today’s advisor
  • AM Best Maintains Stable Outlook on Indonesia’s Non-Life Insurance Segment
  • Owings Mills insurance agent pleads guilty to stealing more than $100,000 in life insurance commissions
Sponsor
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • Lauren Sinnott Named to Ragan’s Top Women in Marketing Awards, Class of 2026 
  • Classic Car Insurer OpenRoad Insurance Expands to 40 U.S. States in Two Years
  • How Aspire General Turned an Early Technology Bet Into Claims Automation at Scale with Kyber
  • Adjusto launches AI-Native contents claims services powered by its technology platform
  • URL Insurance Group Celebrates 40 Years of Service, Growth, and Industry Leadership
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.